ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 223893" data-attributes="member: 13851"><p><strong><u>Key points</u> </strong></p><p><strong></strong></p><p><strong>Question/Objective:</strong><em> What is the safety and efficacy profile of the common compounded bioidentical hormone therapy (cBHT) preparations in perimenopausal and postmenopausal women in the current literature?</em></p><p></p><p><strong>Findings:</strong> <em>Twenty-nine randomized controlled trials (RCTs) (n¼ 1,808) were included. The evaluated cBHT preparations were not associated with adverse changes in lipid profiles or glucose metabolism, endometrial thickness, or serious adverse events. Limited data were available to assess benefits with respect to vasomotor symptoms. No RCT was available to assess clinical events of breast or endometrial cancer or cardiovascular disease. cBHT in the form of vaginal androgen significantly improved vaginal atrophy symptoms.</em></p><p></p><p><strong>Meaning: </strong><em>The meta-analysis found a benefit of cBHT in the form of vaginal androgens for vaginal atrophy symptoms. There are insufficient RCTs currently available to assess the clinical risk of breast cancer, endometrial cancer, or cardiovascular disease. More studies are needed to evaluate the long-term clinical outcomes.</em></p></blockquote><p></p>
[QUOTE="madman, post: 223893, member: 13851"] [B][U]Key points[/U] Question/Objective:[/B][I] What is the safety and efficacy profile of the common compounded bioidentical hormone therapy (cBHT) preparations in perimenopausal and postmenopausal women in the current literature?[/I] [B]Findings:[/B] [I]Twenty-nine randomized controlled trials (RCTs) (n¼ 1,808) were included. The evaluated cBHT preparations were not associated with adverse changes in lipid profiles or glucose metabolism, endometrial thickness, or serious adverse events. Limited data were available to assess benefits with respect to vasomotor symptoms. No RCT was available to assess clinical events of breast or endometrial cancer or cardiovascular disease. cBHT in the form of vaginal androgen significantly improved vaginal atrophy symptoms.[/I] [B]Meaning: [/B][I]The meta-analysis found a benefit of cBHT in the form of vaginal androgens for vaginal atrophy symptoms. There are insufficient RCTs currently available to assess the clinical risk of breast cancer, endometrial cancer, or cardiovascular disease. More studies are needed to evaluate the long-term clinical outcomes.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top